-
untarataa336699
- 960
- 2
- 0
- 0
-
- いいね！0
NASH24x7
@nash24x7
What's your take on #AntidiabeticDrugs in #NAFLD? #ADA2019 @providenceendo @AASLDtweets @EASLedu @GlobalLiver @IntDiabetesFed @AmDiabetesAssn Dr Samir Shah shares a Hepatologists Perspective on AntiDiabetic Drugs pic.twitter.com/EfiaZXrhAQ
2019-06-09 15:39:22
拡大
拡大
拡大
Cristobal Morales
@CristobMorales
Effects of Tirzepatide (TZP), a Novel Dual GIP and GLP-1 Receptor Agonist, on Biomarkers of Nonalcoholic Steatohepatitis (NASH) in Patients with T2D #ada2019 pic.twitter.com/G9HjWZAE5t
2019-06-09 15:13:20
拡大
拡大
拡大
拡大
Cristobal Morales
@CristobMorales
thelancet.com/journals/landi… Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies by Norbert Stefan in #ADA2019 pic.twitter.com/kAd6mmxSTw
2019-06-09 14:51:26
拡大
拡大
拡大
拡大
Shaheen Tomah, MD
@Tomah_Hawk
Dr. Kenneth Cusi of @UFMedicine talking the future of #NASH treatment at @AmDiabetesAssn #ADA2019 pic.twitter.com/a37cVI76JW
2019-06-09 07:40:47
拡大
The Lancet Diabetes & Endocrinology
@TheLancetEndo
Norbert Stefan et al review: Non-alcoholic fatty #liver disease: causes, diagnosis, #cardiometabolic consequences, and treatment strategies bit.ly/2NDm6G6 #NAFLD #diabetes #T2D #obesity #ADA2019 pic.twitter.com/nT8Ar4pMo7
2019-06-09 07:30:00
拡大
The NASH Education Program
@NASH_Education
📽 #ADA2019: Listen to Stephen Harrison, MD, explain #NASH, its characteristics, the risks induced by its progression & highlight its link with #obesity & #diabetes. #NAFLD #FattyLiver #LiverDisease #LiverHealth #NASHedu youtu.be/_S8miEbNuuw
2019-06-09 07:05:09
Matthew Hirschey💡
@matthewhirschey
Major effort is to find accurate biomarkers for #NASH. Need to remember: if you cannot measure it, you cannot target it. #ADA2019 pic.twitter.com/i6tGOWXXEG
2019-06-09 06:16:29
拡大
The NASH Education Program
@NASH_Education
📽 #ADA2019: Watch our video to learn more about the role of the liver and it’s link to #NASH, #obesity and #Type2Diabetes. #NASHedu #FattyLiver #NAFLD #LiverHealth youtube.com/watch?v=k1U7_l…
2019-06-09 06:05:06
The NASH Education Program
@NASH_Education
#ADA2019: Come visit us at booth #1239 & to receive a copy of our #medical monograph about #NAFLD & #NASH as well as our patient brochure, or download them on our website 👉 bit.ly/2P5Celw #NASHedu #FattyLiver #LiverDisease #LiverHealth #PublicHealth pic.twitter.com/02gUmaL4z9
2019-06-09 05:05:04
拡大
The NASH Education Program
@NASH_Education
#ADA2019: #DYK that #NAFLD is more common among #patients with #Type2Diabetes & #MetabolicSyndrome? Download our #medical monograph to learn more 👉 bit.ly/2UnfodT #NASHedu #FattyLiver #LiverHealth #NASH pic.twitter.com/9JlA1LztLg
2019-06-09 04:05:12
拡大
The NASH Education Program
@NASH_Education
📽 #ADA2019: Here is our 3D animation #video about what goes on in the #liver as #NASH #disease progresses. Watch more educational videos on our booth #1239, or visit our website! #NASHedu #FattyLiver #NAFLD #LiverHealth youtube.com/watch?v=7rjKqj…
2019-06-09 03:05:11
GENFIT
@genfit_pharma
#ADA2019: Visit us at booth #1239 to learn more about #NASH & #NAFLD! #LiverDisease @ADA_DiabetesPro pic.twitter.com/O08zxuu2lY
2019-06-09 02:56:34
拡大
GENFIT
@genfit_pharma
#ADA2019: Come see our two late-breaker posters on display:278-LB "#T2D as a risk factor for #NASH" & 279-LB "NIS4™ to identify NASH in type 2 #Diabetes patients"#NAFLD #LiverDisease @HopPitieSalpe @VCUHealth @Pinnacle_TX @UZAnieuws @CHUnantes @institut_thorax @CHU_Lille @Inserm pic.twitter.com/bLbWZ0mdh5
2019-06-09 02:30:17
Shaheen Tomah, MD
@Tomah_Hawk
Thrilled to see increased emphasis on #NASH at @AmDiabetesAssn #ADA2019. Disease recognition is key to the care of patients with #T2D who are at increased risk for #NASH related #cirrhosis and #CVD pic.twitter.com/rkybzsypfc
2019-06-08 14:03:29
拡大
Daniel J Drucker
@DanielJDrucker
Proof-of-concept non-human primate data to support the development of novel liver-targeted mitochondrial uncouplers for the treatment of #NAFLD #NASH and #T2D in humans #ADA2019 @YaleMed pic.twitter.com/8Z0Z1smTXL
2019-06-08 08:45:00
拡大
Gilead Sciences
@GileadSciences
Today marks the beginning of #ADA2019. We’re excited to join the research community to discuss new findings in #NASH. pic.twitter.com/P7wQNev7Nt
2019-06-08 02:47:32
拡大
ExchangeCME
@exchangeCME
Did you know that the #liver disease #NASH affects 7-12% of adults worldwide. #NASHday Learn more tomorrow at our #ADA2019 symposium! Pre-register here: ow.ly/yGf450uyqgT pic.twitter.com/8T5vrz4naT
2019-06-07 06:55:07
拡大